BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...appointed Heiner Dreismann as chairman. He was president and CEO of Roche Molecular Diagnostics in 2000-2006.Imcyse S.A....
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

...Johnson & Johnson (NYSE:JNJ) is behind Provention Bio Inc. (NASDAQ:PRVB) in the interception setting, and Imcyse S.A....
...treatment for Type I diabetes, the anti-TNFα mAb Simponi golimumab, is in Phase I testing. Imcyse...
...will be watching closely to see if these companies can overcome these hurdles. Provention and Imcyse...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

...With €35 million ($39.2 million) in new funding, Imcyse hopes to obtain clinical proof of concept...
...“Many big pharmas are waiting for our clinical results too.” Pierre Vandepapelière, Imcyse Liège, Belgium-based Imcyse S.A....
...different approach than most companies do to tamping down autoimmune responses. Using its Imotopes platform, Imcyse...
Items per page:
1 - 3 of 3
BioCentury | Sep 12, 2020
Management Tracks

New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more

...appointed Heiner Dreismann as chairman. He was president and CEO of Roche Molecular Diagnostics in 2000-2006.Imcyse S.A....
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

...Johnson & Johnson (NYSE:JNJ) is behind Provention Bio Inc. (NASDAQ:PRVB) in the interception setting, and Imcyse S.A....
...treatment for Type I diabetes, the anti-TNFα mAb Simponi golimumab, is in Phase I testing. Imcyse...
...will be watching closely to see if these companies can overcome these hurdles. Provention and Imcyse...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

...With €35 million ($39.2 million) in new funding, Imcyse hopes to obtain clinical proof of concept...
...“Many big pharmas are waiting for our clinical results too.” Pierre Vandepapelière, Imcyse Liège, Belgium-based Imcyse S.A....
...different approach than most companies do to tamping down autoimmune responses. Using its Imotopes platform, Imcyse...
Items per page:
1 - 3 of 3